Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.

NCT02267642 is registered in ClinicalTrials.gov with AbGenomics B.V Taiwan Branch as lead sponsor.

NCT NCT02267642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02267642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Lead sponsor
AbGenomics B.V Taiwan Branch
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2015
Completion date
January 31, 2016
Enrollment
20 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis